A NOVEL METHOD FOR EVALUATING VALUE ASSESSMENT FRAMEWORKS

Author(s)

Bentley TG1, Cohen JT2, Elkin EB3, Huynh J4, Mukherjea A5, Neville TH6, Mei MG7, Copher R8, Knoth RL8, Popescu I9, Zambrano JM1, Chang E1, Broder MS1, Lee J1
1Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA, 2Center for the Evaluation of Value and Risk in Health,Tufts Medical Center, Boston, CA, USA, 3Memorial Sloan-Kettering Cancer Center, New York, CA, USA, 4Hematology Oncology Medical Group of San Fernando Valley, Encino, CA, USA, 5California State University, East Bay, Hayward, CA, USA, 6UCLA Department of Medicine, Los Angeles, CA, USA, 7City of Hope National Medical Center, Duarte, CA, USA, 8Eisai, Inc., Woodcliff Lake, NJ, USA, 9David Geffen School of Medicine at UCLA, Department of Medicine, Los Angeles, CA, USA

Presentation Documents

OBJECTIVES: In response to rising spending in oncology care, various frameworks have been developed to assess the value of oncology drugs. Each framework produces product-specific ratings meant to reflect efficacy, toxicity, quality of life, and quality of evidence. We propose a methodology for evaluating the reliability and validity of such frameworks and provide an example. METHODS: Framework reliability can be assessed using intraclass correlation coefficients (ICC), and convergent validity with Kendall’s W

Conference/Value in Health Info

2016-10, ISPOR Europe 2016, Vienna, Austria

Value in Health, Vol. 19, No. 7 (November 2016)

Code

PRM107

Topic

Methodological & Statistical Research

Topic Subcategory

Modeling and simulation

Disease

Oncology

Explore Related HEOR by Topic

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×